Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Early Postnatal Use of Glibenclamide in Permanent Neonatal Diabetes Secondary to Antenatally Diagnosed KJCN11 Mutation.

Hormone research in paediatrics - 1 Jan 2022

Walton-Betancourth Sandra, Ashford Jennifer, Beardsall Kathy, Gooding Nigel, Gurnell Eleanor M, Hendriks Emile, Hysted Helen, Lee Jenny, Thankamony Ajay, Tseretopoulou Xanthippi, Win Myat, Williams Rachel M

Abstract excerpt

INTRODUCTION: Heterozygous activating mutations in KCNJ11 cause both permanent and transient neonatal diabetes. A minority of patients also have neurological features. Early genetic diagnosis has important therapeutic implications as treatment with sulfonylurea provides good metabolic control and exerts a protective effect on neuromuscular function. CASE PRESENTATION: A term female infant with normal birth weight...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Glucose
Share to Diabetes Mellitus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glyburide

Share to Hypoglycemic Agents

Share to Infant, Newborn, Diseases

Share to Potassium Channels, Inwardly Rectifying

Share to Pregnancy

Share to Sulfonylurea Compounds

Source

Identifiers

PMID: 35817008
DOI: 10.1159/000525989

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Early Postnatal Use of Glibenclamide in Permanent Neonatal Diabetes Secondary to Antenatally Diagnosed KJCN11 Mutation.PMID 35817008Read ↗

Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2.Semantic proximity Read ↗

Familial permanent neonatal diabetes with KCNJ11 mutation and the response to glyburide therapy--a three-year follow-up.Semantic proximity Read ↗

Permanent neonatal diabetes by a new mutation in KCNJ11: unsuccessful switch to sulfonylurea.Semantic proximity Read ↗

Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study.Semantic proximity Read ↗

Comparison of diabetes phenotype in children and their mothers with permanent neonatal diabetes mellitus carrying the same KCNJ11 variants.Semantic proximity Read ↗

Outpatient transition of an infant with permanent neonatal diabetes due to a KCNJ11 activating mutation from subcutaneous insulin to oral glyburide.Semantic proximity Read ↗

Permanent neonatal diabetes mellitus - a case report of a rare cause of diabetes mellitus in East Africa.Semantic proximity Read ↗

Personalized medicine switching from insulin to sulfonylurea in permanent neonatal diabetes mellitus dictated by a novel activating ABCC8 mutation.Semantic proximity Read ↗

Detection of KCNJ11 gene mutations in a family with neonatal diabetes mellitus: implications for therapeutic management of family members with long-standing disease.Semantic proximity Read ↗

Update in neonatal diabetes.Semantic proximity Read ↗

Neonatal diabetes mellitus due to a new KCNJ11 mutation - 10 years of the patient`s follow-up.Semantic proximity Read ↗

Mutations in the Kir6.2 subunit of the KATP channel and permanent neonatal diabetes: new insights and new treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.